Respiratory dysfunction three months after severe COVID-19 is associated with gut microbiota alterations

Background: Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal (GI) tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alte...

Full description

Saved in:
Bibliographic Details
Main Authors: Vestad, Beate, Ueland, Thor, Lerum, Tøri Vigeland, Dahl, Tuva Børresdatter, Holm, Kristian, Barratt-Due, Andreas, Kåsine, Trine, Dyrhol-Riise, Anne Ma, Stiksrud, Birgitte, Tonby, Kristian, Hoel, Hedda, Olsen, Inge Christoffer, Henriksen, Katerina N, Tveita, Anders Aune, Manotheepan, Ravinea, Haugli, Mette, Eiken, Ragnhild, Berg, Åse, Halvorsen, Bente, Lekva, Tove, Ranheim, Trine, Michelsen, Annika Elisabeth, Kildal, Anders Benjamin, Johannessen, Asgeir, Thoresen, Lars, Skudal, Hilde Kristin, Kittang, Bård Reiakvam, Olsen, Roy Bjørkholt, Ystrøm, Carl Magnus, Skei, Nina Vibeche, Hannula, Raisa, Aballi, Saad, Kvåle, Reidar, Skjønsberg, Ole Henning, Aukrust, Pål, Hov, Johannes Espolin Roksund, Trøseid, Marius
Format: Article
Language:English
Subjects:
microbiome
pulmonary function
SARS-CoV-2
Online Access:Request full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background: Although coronavirus disease 2019 (COVID-19) is primarily a respiratory infection, mounting evidence suggests that the gastrointestinal (GI) tract is involved in the disease, with gut barrier dysfunction and gut microbiota alterations being related to disease severity. Whether these alterations persist and are related to long-term respiratory dysfunction remains unknown. Methods: Plasma was collected during hospital admission and after three months from the NOR-Solidarity trial (n = 181) and analysed for markers of gut barrier dysfunction and inflammation. At the three-month follow-up, pulmonary function was assessed by measuring the diffusing capacity of the lungs for carbon monoxide (DLCO ). Rectal swabs for gut microbiota analyses were collected (n = 97) and analysed by sequencing the 16S rRNA gene. Results: Gut microbiota diversity was reduced in COVID-19 patients with respiratory dysfunction, defined as DLCO below the lower limit of normal three months after hospitalisation. These patients also had an altered global gut microbiota composition, with reduced relative abundance of 20 bacterial taxa and increased abundance of five taxa, including Veillonella, potentially linked to fibrosis. During hospitalisation, increased plasma levels of lipopolysaccharide-binding protein (LBP) were strongly associated with respiratory failure, defined as pO2 /fiO2 -(P/F ratio)